5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
NEUTRAL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.18▼ | 1.17▲ | 1.17▲ | 1.26▼ | 1.53▼ |
MA10 | 1.17▲ | 1.17▲ | 1.18▼ | 1.34▼ | 2.77▼ |
MA20 | 1.16▲ | 1.19▼ | 1.21▼ | 1.60▼ | 4.27▼ |
MA50 | 1.18▼ | 1.25▼ | 1.30▼ | 3.01▼ | 6.25▼ |
MA100 | 1.20▼ | 1.32▼ | 1.53▼ | 4.45▼ | 6.99▼ |
MA200 | 1.24▼ | 1.57▼ | 1.61▼ | 6.11▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | 0.002▲ | 0.003▲ | 0.057▲ | -0.344▼ |
RSI | 51.330▲ | 41.571▼ | 37.184▼ | 28.929▼ | 26.298▼ |
STOCH | 77.222 | 23.313 | 20.109 | 7.511▼ | 4.846▼ |
WILL %R | -37.500 | -64.286 | -75.000 | -98.451▼ | -99.780▼ |
CCI | 92.485 | -10.045 | -49.673 | -97.880 | -87.625 |
Monday, May 05, 2025 06:55 AM
A downtrend has been apparent in Acrivon Therapeutics, Inc. (ACRV) lately. While the stock has lost 14% over the past week, it could witness a trend reversal as a hammer chart pattern was formed ...
|
Friday, April 25, 2025 09:58 AM
Real time quote data is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
|
Friday, April 25, 2025 05:13 AM
April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
09/05/25 | 1.21 | 1.22 | 1.1449 | 1.16 | 641,004 |
08/05/25 | 1.24 | 1.25 | 1.16 | 1.18 | 530,144 |
07/05/25 | 1.31 | 1.369 | 1.17 | 1.23 | 686,584 |
06/05/25 | 1.41 | 1.42 | 1.2705 | 1.33 | 507,008 |
05/05/25 | 1.41 | 1.50 | 1.36 | 1.42 | 537,359 |
02/05/25 | 1.39 | 1.42 | 1.325 | 1.41 | 654,701 |
01/05/25 | 1.44 | 1.49 | 1.32 | 1.33 | 975,782 |
30/04/25 | 1.43 | 1.55 | 1.40 | 1.40 | 915,436 |
29/04/25 | 1.46 | 1.52 | 1.395 | 1.44 | 673,493 |
28/04/25 | 1.70 | 1.70 | 1.51 | 1.55 | 814,507 |
|
|
||||
|
|
||||
|
|